Description

1. Cefpodoxime Proxetil IP 50 mg + Potassium Clavulanic acid 31.125 mg
2. Cefpodoxime 200 mg + Clavulanate 125 mg

The pathogens causing Respiratory Tract Infections are susceptible to beta-lactam antibiotics that include penicillins and cephalosporins.

While first- and second-generation cephalosporins could only be administered by intravenous or intramuscular injection, the development of third generation cephalosporins that are broad-spectrum and can be administered orally has significantly increased their value in the management of RTIs.

Cefpodoxime

Drug class: Cephalosporin antibiotics

• Cefpodoxime is a third-generation semisynthetic cephalosporin stable towards the most commonly found plasmid-mediated beta-lactamases.

• It has a broad spectrum of antibacterial activity encompassing both Gram-negative and Gram-positive bacteria, rendering it a possible option for empirical use in a wide range of community acquired infections in both adult and paediatric patients.

Clavulanate

Drug class: Beta-lactamase inhibitors

• Clavulanate potassium is structurally related to penicillin and possesses the ability to inactivate a wide variety of beta-lactamase enzymes, thereby preventing the inactivation of the combining antibiotics, such as amoxicillin and cefpodoxime.

• Clavulanic acid alone does not exert any clinically effective antibacterial effect.

Combination – Cefpodoxime Plus Clavulanic Acid

• The presence of clavulanate potassium in the cefpodoxime-clavulanic acid combination further extends the antibiotic spectrum of cefpodoxime to include many bacteria normally resistant to cefpodoxime alone.

• The mean Minimal Inhibitory Concentration values of cefpodoxime plus clavulanic acid are significantly lower in comparison with that of amoxicillin plus clavulanic acid for S. aureus.